Neurocrine Biosciences, Inc. Share Price Börse Stuttgart
Equities
NB3
US64125C1099
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
123.4 EUR | -1.48% | -3.52% | +4.22% |
05-31 | Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing | MT |
05-28 | Neurocrine Biosciences Says CEO Kevin Gorman Retiring | MT |
Sales 2024 * | 2.22B 2.05B 174B | Sales 2025 * | 2.55B 2.35B 200B | Capitalization | 13.63B 12.57B 1,070B |
---|---|---|---|---|---|
Net income 2024 * | 426M 393M 33.44B | Net income 2025 * | 667M 615M 52.35B | EV / Sales 2024 * | 5.24 x |
Net cash position 2024 * | 2B 1.84B 157B | Net cash position 2025 * | 2.81B 2.59B 221B | EV / Sales 2025 * | 4.24 x |
P/E ratio 2024 * |
33.4
x | P/E ratio 2025 * |
21.4
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.2% |
Latest transcript on Neurocrine Biosciences, Inc.
1 week | -3.52% | ||
1 month | -3.89% | ||
3 months | +0.04% | ||
6 months | +16.31% | ||
Current year | +4.22% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Director of Finance/CFO | 44 | 31/10/17 | |
Jude Onyia
CTO | Chief Tech/Sci/R&D Officer | 60 | 29/11/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 31/03/99 |
George Morrow
BRD | Director/Board Member | 72 | 30/09/15 |
Kevin Gorman
FOU | Founder | 66 | 31/12/91 |
Date | Price | Change |
---|---|---|
31/05/24 | 123.4 | -1.48% |
30/05/24 | 125.2 | -1.80% |
29/05/24 | 127.6 | -0.97% |
28/05/24 | 128.8 | +1.10% |
27/05/24 | 127.4 | -0.39% |
Delayed Quote Börse Stuttgart, May 31, 2024 at 04:56 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- NBIX Stock
- NB3 Stock